Boehringer Ingelheim and Eli Lilly & Company launch type 2 diabetes educational game, "Complications Combat"

Boehringer IngelheimBoehringer Ingelheim and Eli Lilly & Company have launched an educational digital game for type 2 diabetes called Complications Combat. The game, available for desktop and iPad users, is designed to raise awareness of the many complications associated with type 2 diabetes and the challenges physicians and patients face when considering and managing these on a daily basis.

"The aim and design of the game is simple," said Arnd Prilipp, Launch and Established Products CVM Boehringer Ingelheim. "However, effective management of type 2 diabetes and its complications is not. To simulate this, players are tasked with simultaneously saving the healthy lifestyle items whilst combating the many complications - and it is not easy."

The objective of the game is to effectively manage type 2 diabetes and its complications by clicking or swiping the complications and 'friends', which are the healthy steps for managing the condition, to the correct side of the screen to maintain optimal patient health for as long as possible. During the course of the game, the user learns about the diverse range of complications that can be associated with type 2 diabetes and also about positive lifestyle choices that can help combat the progression of the disease. As the game becomes increasingly difficult, the user learns just how challenging it can be for physicians and patients to take all of these complications and lifestyle choices into consideration at the same time.

Uncontrolled type 2 diabetes can lead to hyperglycaemia which, if untreated in the long-term, can cause serious medical complications in all parts of the body.(1) Diabetes-related complications include cardiovascular disease, stroke, kidney disease, eye problems and foot ulcers.(2)

Complications Combat can be played at www.complicationscombat.com and iPad users can download the free touchscreen app at https://itunes.apple.com/hk/app/complication-combat-how-long/id640173022?mt=8.

About Diabetes
An estimated 371 million people worldwide have Type 1 and Type 2 Diabetes.(1) Type 2 Diabetes is the most common type, accounting for an estimated 90% of all diabetes cases.(3) Diabetes is a chronic disease that occurs when the body either does not properly produce, or use, the hormone insulin.(4)

Boehringer Ingelheim and Eli Lilly and Company
In January 2011, Boehringer Ingelheim and Eli Lilly and Company announced an alliance in the field of diabetes that centers on three compounds representing several of the largest treatment classes. This alliance leverages the companies' strengths as two of the world's leading pharmaceutical companies, combining Boehringer Ingelheim's solid track record of research-driven innovation and Lilly's innovative research, experience, and pioneering history in diabetes. By joining forces, the companies demonstrate commitment in the care of patients with diabetes and stand together to focus on patient needs.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

In 2012, Boehringer Ingelheim achieved net sales of about 14.7 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 22.5% of its net sales.

About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organisations. Headquartered in Indianapolis, IN, Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs.

1. International Diabetes Federation. Available at: www.idf.org. Last accessed January 2013.
2. Dang CN BA. Changing perspectives in diabetic foot ulcer management. Int J Low Extrem Wounds 2003;2(1)::4-12.
3. World Health Organization. Fact Sheet No. 312 Diabetes 2009 [cited 2013 January 2013]; Available from: http://www.who.int/mediacentre/factsheets/fs312/en/index.html#
4. International Diabetes Federation. What is Diabetes? IDF Diabetes Atlas. 2011; (5th Edition).

Most Popular Now

Delivering insulin in a pill

Given the choice of taking a pill or injecting oneself with a needle, most of us would opt to regulate a chronic health condition by swallowing a pill. But for millions o...

Probiotics can protect the skeletons of older wome…

For the first time in the world, researchers at the University of Gothenburg, Sweden, have demonstrated that probiotics, dietary supplements with health-promoting bacteri...

Alzheimer's breakthrough: Brain metals that may dr…

Alzheimer's disease could be better treated, thanks to a breakthrough discovery of the properties of the metals in the brain involved in the progression of the neurodegen...

FDA approves first drug comprised of an active ing…

The U.S. Food and Drug Administration today approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with two rare and severe forms o...

Can aspirin treat Alzheimer's?

A regimen of low-dose aspirin potentially may reduce plaques in the brain, which will reduce Alzheimer's disease pathology and protect memory, according to neurological r...

In mice, stem cells seem to work in fighting obesi…

Obesity is an increasing global health problem associated with several comorbidities and a high risk of mortality. A wide spectrum of interventions has been proposed for ...

FDA takes steps to foster greater efficiency in bi…

Today, the agency withdrew the draft guidance, "Statistical Approaches to Evaluate Analytical Similarity," issued in September 2017. The draft guidance, if finalized as w...

Research shows how a moderate dose of alcohol prot…

For at least 20 years, research has shown that for many people, moderate consumption of alcohol can protect the heart, but the reason for this is poorly understood. A stu...

'Kiss of death' cancer

It's called the 'kiss of death'. Triple negative breast cancer has no targeted drug therapy and, as such, the only hope for these patients is chemotherapy. Triple negativ...

Some existing anti-cancer drugs may act in part by…

Bolstering the notion that RNA should be considered an important drug-discovery target, scientists at Scripps Research have found that several existing, FDA-approved anti...

Novartis Clear about Psoriasis survey data highlig…

Novartis announced today the publication of global Clear about Psoriasis survey data in the Journal of the European Academy of Dermatology and Venereology[1]. The publica...

Poliovirus therapy for recurrent glioblastoma has …

A genetically modified poliovirus therapy developed at Duke Cancer Institute shows significantly improved long-term survival for patients with recurrent glioblastoma, wit...